Functional Foods & Nutraceuticals Patents: Top Filers & Trends 2026
- Concentrated at the top. The five leading assignees together hold 853 of 1,719 records in scope (49.6%), with a long tail behind them.
- Filing has cooled from its peak. Activity peaked at 153 records in 2020; from 2021 to 2024, the last complete filing year, counts fell 56%, from 102 to 45.
- Medicinal and food classes overlap heavily. A61K and A23L each cover about 44% of records, showing most filings straddle the food-drug boundary rather than sitting in one lane.
Filing growth compares 2021 (102 records) with 2024 (45) — a three-year span. 2024 is the most recent year we treat as complete: publication lags filing by roughly 18 months, so 2025 onwards are still filling in and any growth rate that ends there would understate the field. Top-5 share is the combined record count of the five largest assignees divided by all 1,719 records in scope (CR5), not by the ranked leaders only.
What the functional foods and nutraceuticals patent record shows
Functional foods and nutraceuticals sit at the intersection of food science, microbiology and pharmaceutical formulation, and the patent record reflects that mix directly. Filings in this dataset span ingredient mixtures, microbial cultures, processing temperature controls, product stability and flavor compound work, meaning claims can originate from a food processor, a probiotics house or a pharmaceutical formulator depending on the specific mechanism being protected. That breadth is why the leading IPC classes split almost evenly between medicinal preparations and conventional food categories rather than clustering in one.
The scope covers 1,719 published records from 2015 through the 2026-08-31 cut-off. Because publication typically lags filing by around 18 months, the most recent one to two years understate real filing activity and should be read as provisional rather than a genuine decline.
Filing trend and technology composition
Two views of the same 1,719 records: how filing volume has moved year over year, and which IPC subclasses carry the claim density.
A 2020 peak followed by a documented pullback
Filings rose from 81 in 2017 to a peak of 153 in 2020, then fell across the 2021-2024 window that can be treated as complete, dropping 56% from 102 to 45. Counts for 2025 and 2026 are still filling in under normal publication lag and should not be read as a continued decline.
Medicinal and food classes dominate, microbiology close behind
A61K (medicinal preparations) and A23L (foods and non-alcoholic beverages) each sit near 44% of the 1,719 records, with C12N (microorganisms and genetic engineering) close behind at 36.8%. Because a single record can carry multiple IPC codes, these shares add to well over 100% and should each be read against the full record count, not against each other.
Shares are the percentage of the 1,719 records in scope. A patent can carry several IPC classes, so the shares add up to more than 100%.
Go deeper on Functional Foods & Nutraceuticals Patent Landscape with Eureka
This page is one run against one query. Ask Eureka your own question about functional foods & nutraceuticals patent landscape and every answer comes back with the patent numbers behind it.
Try EurekaMost-cited records and a recent representative filing
Hericium erinaceus strain HE015, molecular markers and uses thereof (US20250333805A1)
Filed by Infinitus (China) Company Ltd. and published 2025-10-30, this filing discloses a newly bred Hericium erinaceus (lion's mane) fungal strain, HE015, obtained through systematic breeding from wild-collected material and deposited at the Guangdong Microbial Culture Collection Center. The claims center on the strain's distinct genetic markers and its use, positioning it within the microbial-culture and functional-ingredient overlap that runs through much of this dataset.Abstract trimmed for length; see the full record for complete claim language.
| # | Publication no. | Patent title | Citations |
|---|---|---|---|
| 1 | WO2007025097A2 | use | 616 |
| 2 | WO2008108989A2 | Cultures with improved phage resistance | 405 |
| 3 | US20100093617A1 | Use | 355 |
| 4 | US20070118916A1 | Process for the production of fine chemicals | 350 |
| 5 | US20140199767A1 | use | 344 |
| 6 | US20130011828A1 | Use | 216 |
| 7 | WO2008004900A1 | Production of ultrapure EPA and polar lipids from largely heterotrophic culture | 209 |
| 8 | US20060093720A1 | Pumpable, semi-solid low calorie sugar substitute compositions | 209 |
| 9 | US20110002889A1 | Cultures with Improved Phage Resistance | 204 |
| 10 | US20100069492A1 | Production of ultrapure EPA and polar lipids from largely heterotrophic culture | 168 |
Citation counts accumulate over time, so older records are structurally favoured; treat this as a signal of past influence rather than current commercial weight.
Each row carries its publication number; clicking a row searches Eureka by that number.
Put your own technology through the same analysis
Eureka on the web
When you want the answer in the next five minutes.
The agent works the prompt against patents and technical literature, citing every source.
Run your analysis now →MCP server & REST API
When it has to run inside your own pipeline.
Patent search, landscape analysis and assignee resolution as MCP tools. Drop them into any agent framework, or call REST directly.
Browse MCP servers →What the numbers mean for a filing decision
Three patterns stand out once concentration, timing and class overlap are read together.
The leader board is short and heavy
The top five assignees combined account for 853 of the 1,719 records in scope, 49.6% of the field, while the leader alone holds 494. That leaves a long tail of single- and few-filing entrants competing for the remaining claim space.
Post-peak activity has genuinely declined
After peaking at 153 records in 2020, filings fell from 102 in 2021 to 45 in 2024, the last year that can be treated as complete. That is a real pullback in a window unaffected by publication lag, distinct from the incomplete 2025-2026 data.
Food and medicinal claims sit on top of each other
A61K and A23L cover almost identical shares of the dataset, and C12N follows at 36.8%. Filings frequently claim across the food-drug boundary and into microbial-culture mechanics rather than staying inside a single classification.
Eureka can read the same corpus for gaps instead of for coverage: under-claimed branches adjacent to functional foods & nutraceuticals patent landscape, with the prior art for and against each one.
Who holds the claim space, and where it thins out
A short list of assignees anchors more than half the ranked field, while several of the most active names show no recent-year filings, suggesting the position has already been staked out rather than actively expanding.
One assignee dominates the ranking
The leading assignee holds 494 of the 1,719 records in scope, well ahead of fifth place at 55 and tenth place at 18. That gap suggests an early, sustained filing programme rather than a recent surge.
Concentration extends past the top five
The top ten assignees combined hold 991 records, 57.6% of all records in scope. The step down from fifth (55) to tenth (18) is steep, meaning most of that concentration sits in the first few positions.
Leading filers have gone quiet recently
Several of the most active historical assignees show zero filings in the latest year, with year-over-year change of -100% for some. Given publication lag, this may reflect filings still working through the pipeline rather than an actual exit from the space.
| Assignee | Recent year | YoY |
|---|---|---|
| International Flavors & Fragrances (Denmark) ApS | 0 | -100% |
| Nicoventures Trading Ltd | 0 | -100% |
| Ghent University | 0 | -100% |
| Genecor International Inc. | 0 | — |
| Microbial Resource Management Health NV | 0 | -100% |
| Pharmalink International Ltd | 0 | — |
| Second Genome Inc. | 0 | — |
| Metanomics GmbH | 0 | — |
Where to take this analysis
The dataset points to specific next steps depending on whether the goal is freedom-to-operate, competitive tracking or identifying open claim space.
Check freedom-to-operate against the top holders
With the leading assignee alone holding 494 records, any new filing touching microbial-culture or stability claims should be checked against that portfolio first.
Run a freedom-to-operate search in EurekaTrack dormant leaders for renewed activity
Several top assignees show zero filings in the latest year; publication lag means that could reverse. Set up monitoring rather than assuming the position is settled.
Set up assignee monitoring in EurekaScope claims in the under-claimed branches
Animal-feed carriers, dairy-matrix delivery and processing-temperature control for live cultures show lighter coverage relative to the dominant classes.
Explore white space in EurekaCommon questions on the functional foods and nutraceuticals patent landscape
The ranking is led by a single assignee holding 494 of the 1,719 records in scope, far ahead of the rest of the field. The top five assignees combined hold 853 records, 49.6% of the total, and the top ten hold 991, or 57.6%. Beyond the top ten the field thins quickly into a long tail of assignees with far fewer filings each, so competitive tracking should focus on the leading names rather than the full ranked list.
Filing peaked at 153 records in 2020 and has declined since, with the last complete comparison window showing a drop from 102 records in 2021 to 45 in 2024, a 56% fall. Data for 2025 and 2026 is still incomplete because publication typically lags filing by about 18 months, so those years understate real activity and should not be read as confirming a continued decline. The safest read is that the field has cooled meaningfully from its 2020 peak through 2024.
Medicinal preparations (A61K) and foods and non-alcoholic beverages (A23L) each cover close to 44% of the 1,719 records, essentially tied for the largest share. Microorganisms and genetic engineering (C12N) follows at 36.8%, reflecting how much of this field relies on microbial-culture and fermentation mechanisms. Because records often carry multiple IPC codes, these categories overlap heavily rather than representing separate, competing segments.
US20250333805A1, filed by Infinitus (China) Company Ltd. and published 2025-10-30, claims a specific new strain of Hericium erinaceus (lion's mane), HE015, defined by its molecular markers and deposited under a named accession number. It does not block work on lion's mane generally; it protects this particular bred strain and its identified genetic markers. Anyone developing a competing strain-based ingredient should confirm their material is genetically distinct from HE015 rather than avoiding the species altogether.
Relative to the dominant A61K, A23L and C12N classes, categories like animal feed (A23K, 10.5% of records), dairy products (A23C, 10.2%) and enzyme-based measuring and testing (C12Q, 9.8%) carry noticeably lighter documented coverage. That does not guarantee an easy grant, but it does suggest less crowded prior art in areas like dairy-matrix delivery formats or processing-temperature control specific to live microbial cultures. Any white-space claim should still be checked against the leading assignees' portfolios, since dominant filers may hold adjacent claims even in lighter-covered classes.
Research Functional Foods & Nutraceuticals Patent Landscape in depth with Eureka
Go past this page: query the whole functional foods & nutraceuticals patent landscape corpus yourself, in your own scope.
Every answer comes back with patent numbers you can open.
Disclaimer. This page is generated from Patsnap Eureka data drawn from a limited snapshot of global patent and scientific-literature records, and is provided for general information and reference only.
Patent data carries inherent limitations: recent filings (typically the most recent 18–24 months) are under-counted due to standard publication lag; counts may be reported at either a patent-family or a patent-record basis and are not always directly comparable; classification, applicant-name, and citation data may contain errors, duplicates, or omissions; and the underlying search query defines and constrains the scope shown. As a result, the analysis may be incomplete or inaccurate and may not reflect the full technology landscape.
Nothing on this page constitutes an exhaustive prior-art, novelty, freedom-to-operate, or validity search, nor does it constitute legal, financial, investment, or professional advice, and it should not be relied upon as such. Any patent, commercial, or strategic decision should be verified independently and reviewed with qualified patent, legal, and domain professionals. Patsnap makes no warranties, express or implied, as to the accuracy, completeness, or fitness for any particular purpose of the information presented.
Machine translation. Assignee and organisation names originally recorded in Chinese, Japanese or Korean have been rendered into English by an AI translation step so that the tables stay readable. These renderings are best-effort and may not match a company’s registered English name; the original name is what the underlying patent record carries, and it is what any Eureka query launched from this page uses.